专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08673548B2 Genes and polypeptides relating to breast cancers 有权
标题翻译：与乳腺癌相关的基因和多肽
公开(公告)号：US08673548B2
公开(公告)日：2014-03-18
申请号：US12377024
申请日：2007-08-10
申请人： Yusuke Nakamura , Toyomasa Katagiri , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Toyomasa Katagiri , Shuichi Nakatsuru
IPC分类号： C12Q1/00 , C07K14/00
CPC分类号： C07K16/18 , A61K31/7088 , C07K14/47 , C07K14/4748 , C12N2310/14 , C12Q1/485 , G01N33/5011 , G01N33/5035 , G01N33/57415 , G01N2333/9121 , G01N2510/00
摘要： The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.
摘要翻译：本申请提供了新的人类基因A7322，其表达在乳腺癌中显着升高。本申请还提供了人类基因F3374，其在乳腺癌中的表达显着升高。由此编码的这些基因和多肽可用于例如乳腺癌的诊断，以及用于开发针对乳腺癌的药物的靶分子。本发明的特征在于筛选PBK / TOPK的激酶活性的调节剂的方法。本发明还提供筛选用于预防或治疗癌症（例如乳腺癌）的药剂的方法。

2. 发明申请

US20120022128A1 PKIB and NAALADL2 for Target Genes of Prostate Cancer Therapy and Diagnosis 审中-公开
标题翻译： PKIB和NAALADL2用于前列腺癌治疗和诊断的靶基因
公开(公告)号：US20120022128A1
公开(公告)日：2012-01-26
申请号：US12674664
申请日：2008-08-20
申请人： Yusuke Nakamura , Hidewaki Nakagawa , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Hidewaki Nakagawa , Shuichi Nakatsuru
IPC分类号： A61K31/713 , C12N15/63 , C12Q1/68 , A61P35/00 , C40B30/04 , C07K16/44 , C07K16/18 , G01N33/566 , C12N15/113 , G01N33/574
CPC分类号： A61K31/70 , A61K48/00 , C07K14/47 , C12N15/113 , C12N2310/111 , C12N2310/14
摘要： The invention features methods for detecting prostate cancer, especially hormone-refractory prostate cancer (HRPC) or castration-resistant prostate cancer (CRPC), by detecting over-expression of PKIB or NAALADL2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing prostate cancer including HRPC, based on the over-expression of PKIB or NAALADL2 in the prostate cancer, the cell proliferation function of PKIB or NAALADL2, the intracellular localization of PKIB or NAALADL2 or the interaction between PKIB and PKA-C. Also, provided are a method for treating prostate cancer by administering a double-stranded molecule against the PKIB or NAALADL2 gene. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.
摘要翻译：本发明通过检测PKIB或NAALADL2的过表达来检测前列腺癌，特别是激素难治性前列腺癌（HRPC）或去势抗性前列腺癌（CRPC）的方法。还公开了基于前列腺癌中PKIB或NAALADL2的过度表达，PKIB或NAALADL2的细胞增殖功能，PKIB或NAALADL2的细胞内定位或相互作用的鉴定，鉴定用于治疗和预防前列腺癌包括HRPC的化合物的方法 PKIB和PKA-C之间。此外，提供了通过对PKIB或NAALADL2基因施用双链分子来治疗前列腺癌的方法。本发明还提供了包括双链分子和编码它们的载体的产物，以及可用于所提供的方法中的包含分子或载体的组合物。

3. 发明授权

US08067153B2 Genes and polypeptides relating to prostate cancers 失效
标题翻译：与前列腺癌相关的基因和多肽
公开(公告)号：US08067153B2
公开(公告)日：2011-11-29
申请号：US11913233
申请日：2006-07-19
申请人： Yusuke Nakamura , Hidewaki Nakagawa , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Hidewaki Nakagawa , Shuichi Nakatsuru
IPC分类号： C12Q1/00
CPC分类号： G01N33/57434 , A61K38/1709 , C07K14/4748 , C12Q1/48 , G01N33/573 , G01N2333/91051 , G01N2500/00
摘要： The present application provides novel human gene ELOVL7 whose expression is markedly elevated in prostate cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.
摘要翻译：本申请提供了新型人类基因ELOVL7，其表达在前列腺癌中显着升高。由该基因编码的基因和多肽可用于例如前列腺癌的诊断中，作为用于开发针对该疾病的药物的靶分子，以及用于减轻前列腺癌的细胞生长。

4. 发明申请

US20110263012A1 SCREENING AND THERAPEUTIC METHOD FOR NSCLC TARGETING CDCA1-KNTC2 COMPLEX 审中-公开
标题翻译：用于NSCLC靶向CDCA1-KNTC2复合物的筛选和治疗方法
公开(公告)号：US20110263012A1
公开(公告)日：2011-10-27
申请号：US13080461
申请日：2011-04-05
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： C12N15/63 , C07H21/02
CPC分类号： G01N33/57423 , G01N2500/02
摘要： The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.
摘要翻译：本发明是基于CDCA1和KNTC2的共激活及其同源相互作用在肺癌进展中起重要作用的观察，并且抑制复合物的方法可用于治疗非小细胞肺癌。

5. 发明授权

US07700573B2 Method for diagnosing non-small lung cancer 失效
标题翻译：诊断非小细胞肺癌的方法
公开(公告)号：US07700573B2
公开(公告)日：2010-04-20
申请号：US10593842
申请日：2005-03-18
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K31/70 , A01N43/64
CPC分类号： A61K31/731 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
摘要翻译：公开了使用差异表达基因KIF11，GHSR1b，NTSR1和FOXM1检测非小细胞肺癌（NSCLC）的方法。还公开了基于KOC1和KIF11或NMU和GHSR1b或NTSR1之间的相互作用鉴定用于治疗和预防NSCLC的化合物的方法。

6. 发明申请

US20100009920A1 TTK AS TUMOR MARKER AND THERAPEUTIC TARGET FOR LUNG CANCER 审中-公开
标题翻译： TTK作为肿瘤标志物和肺癌的治疗目标
公开(公告)号：US20100009920A1
公开(公告)日：2010-01-14
申请号：US12518876
申请日：2007-12-12
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K38/10 , C07K16/00 , C07H21/04 , C07K14/00 , A61K31/7088 , A61P35/00 , C12Q1/68 , C07K7/08
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed herein is a method for determining kinase activity of TTK for EGFR and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer that use or include such modulators. Methods for diagnosing lung cancer using the kinase activity of TTK for EGFR protein as an index as well as methods for assessing and prognosing lung cancer are also provided.
摘要翻译：本文公开了用于确定EGFR的TTK的激酶活性的方法和筛选该激酶活性的调节剂的方法。还公开了用于预防和/或治疗使用或包括这种调节剂的肺癌的方法和药物组合物。还提供了使用TTK对EGFR蛋白的激酶活性作为指标诊断肺癌的方法以及肺癌的评估和预后的方法。

7. 发明申请

US20090317392A1 METHOD OF DIAGNOSING SMALL CELL LUNG CANCER 审中-公开
标题翻译：诊断小细胞肺癌的方法
公开(公告)号：US20090317392A1
公开(公告)日：2009-12-24
申请号：US11913273
申请日：2006-07-26
申请人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yataro Daigo , Shuichi Nakatsuru
IPC分类号： A61K39/395 , A61K39/00 , C12Q1/68 , G01N33/53 , C12N15/63 , C40B30/04 , A61K31/7088 , C07H21/02
CPC分类号： C12N15/1135 , C12N2310/14 , C12Q1/6886 , C12Q2600/136
摘要： Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histological types of lung cancer, non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer and method for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or molecular targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected.
摘要翻译：本文描述了用于检测和诊断小细胞肺癌（SCLC）的客观方法。在一个实施方案中，所述诊断方法涉及确定区分SCLC细胞和正常细胞的SCLC相关基因的表达水平。在另一个实施方案中，诊断方法包括确定区分肺癌，非小细胞肺癌（NSCLC）和SCLC的两种主要组织学类型的SCLC相关基因的表达水平。最后，本发明提供了筛选用于治疗小细胞肺癌的治疗剂，治疗小细胞肺癌的方法和接种针对小细胞肺癌的受试者的方法。此外，本发明提供抗化学疗法的肺癌或SCLC相关基因作为用于这些癌症的治疗剂的诊断标记和/或分子靶标。这些基因在化疗耐药性肺癌或SCLC中上调。因此，可以使用基因的表达水平作为诊断标记来预测化学耐药性肺癌或SCLC。结果，可以避免无效化疗引起的任何不良反应，可以选择更合适有效的治疗策略。

8. 发明申请

US20090175844A1 METHOD OF DIAGNOSING BLADDER CANCER 失效
标题翻译：诊断乳腺癌的方法
公开(公告)号：US20090175844A1
公开(公告)日：2009-07-09
申请号：US11815850
申请日：2006-02-09
申请人： Yusuke Nakamura , Toyomasa Katagiri , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Toyomasa Katagiri , Shuichi Nakatsuru
IPC分类号： A61K39/395 , C12Q1/68 , C40B30/00 , C07K14/00 , C07H21/02 , C12N15/63 , C12N5/10 , C12P21/02 , C07K16/00 , A61K31/7105 , A61K38/16 , A61P35/00
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/57407 , G01N2500/00
摘要： Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.
摘要翻译：本文描述了膀胱癌（BLC）检测和诊断的客观方法。在一个实施方案中，诊断方法涉及确定鉴别BLC细胞和正常细胞的BLC相关基因的表达水平。本发明还提供了使用具有淋巴结转移的膀胱癌细胞中具有独特改变的表达模式的BLC相关基因来预测和预防膀胱癌转移的手段。最后，本发明提供筛选可用于治疗膀胱癌的治疗剂，治疗膀胱癌的方法和接种疫苗接种膀胱癌的方法。特别地，本申请提供了新的人基因C2093，B5860Ns和C6055，其表达在膀胱癌中显着升高。由该基因编码的基因和多肽可用于例如膀胱癌的诊断，作为用于开发针对该疾病的药物的靶分子，以及用于减轻膀胱癌的细胞生长。

9. 发明申请

US20090169572A1 METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-CDH3 ANTIBODIES 审中-公开
标题翻译：使用抗CDH3抗体的影响功能破坏细胞的方法
公开(公告)号：US20090169572A1
公开(公告)日：2009-07-02
申请号：US12280956
申请日：2007-02-28
申请人： Shuichi Nakatsuru , Megumi Yoshikawa , Shinichi Hiroshima
发明人： Shuichi Nakatsuru , Megumi Yoshikawa , Shinichi Hiroshima
IPC分类号： A61K39/00 , C07K16/18 , C12N5/06
CPC分类号： C07K16/30 , C07K2317/732
摘要： The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.
摘要翻译：本发明涉及基于抗CDH3抗体的效应子功能的细胞毒性的用途。具体地，本发明提供了包含抗CDH3抗体作为活性成分的方法和药物组合物，用于使用抗体效应子功能损伤表达CDH3的细胞。由于CDH3在胰腺，肺癌，结肠癌，前列腺癌，乳腺癌，胃癌或肝癌细胞中强烈表达，本发明可用于胰腺，肺癌，结肠癌，前列腺癌，乳腺癌，胃癌或肝癌的治疗。

10. 发明授权

US07531300B2 Method of diagnosing breast cancer 有权
标题翻译：诊断乳腺癌的方法
公开(公告)号：US07531300B2
公开(公告)日：2009-05-12
申请号：US10573297
申请日：2004-09-24
申请人： Yusuke Nakamura , Toyomasa Katagiri , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Toyomasa Katagiri , Shuichi Nakatsuru
IPC分类号： C12Q1/00
CPC分类号： C12Q1/6886 , C07K14/4702 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/57415 , G01N2500/04
摘要： Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS and IDC cells. The present invention further provides means for predicting and preventing breast cancer metastasis using BRC-associated genes having unique altered expression patterns in breast cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and method for vaccinating a subject against breast cancer.
摘要翻译：本文描述了用于检测和诊断乳腺癌（BRC）的客观方法。在一个实施方案中，诊断方法涉及确定区分BRC细胞和正常细胞的BRC相关基因的表达水平。在另一个实施方案中，诊断方法涉及确定鉴别BRC细胞之间，DCIS和IDC细胞之间的BRC相关基因的表达水平。本发明还提供了使用具有淋巴结转移的乳腺癌细胞中具有独特改变的表达模式的BRC相关基因预测和预防乳腺癌转移的方法。最后，本发明提供了筛选用于治疗乳腺癌的治疗剂的方法，以及用于治疗乳腺癌的方法以及接种受试者对乳腺癌的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式